Frances P O'Malley

Summary

Affiliation: Mount Sinai Hospital
Country: Canada

Publications

  1. doi Lobular neoplasia: morphology, biological potential and management in core biopsies
    Frances P O'Malley
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Mod Pathol 23:S14-25. 2010
  2. pmc Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry
    Letitia D Smith
    Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Melbourne, Victoria 3010, Australia
    Breast Cancer Res 13:R14. 2011
  3. pmc The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer
    Esther M John
    Clinical and Genetic Epidemiology Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
    Breast Cancer Res 6:R375-89. 2004
  4. doi An update on apocrine lesions of the breast
    F P O'Malley
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Histopathology 52:3-10. 2008
  5. ncbi The spectrum of apocrine lesions of the breast
    F P O'Malley
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Adv Anat Pathol 11:1-9. 2004
  6. doi HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab
    Frances P O'Malley
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5
    Arch Pathol Lab Med 132:61-5. 2008
  7. ncbi Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast
    Frances P O'Malley
    Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Mod Pathol 19:172-9. 2006
  8. ncbi JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer
    Michael Reedijk
    Department of Surgical Oncology, University of Toronto, Toronto, ON, Canada, M5G 2M9
    Breast Cancer Res Treat 111:439-48. 2008
  9. pmc Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors
    Anita L Bane
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 117:183-91. 2009
  10. ncbi Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast
    Teresa L Mastracci
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    Genes Chromosomes Cancer 45:1007-17. 2006

Collaborators

Detail Information

Publications37

  1. doi Lobular neoplasia: morphology, biological potential and management in core biopsies
    Frances P O'Malley
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Mod Pathol 23:S14-25. 2010
    ....
  2. pmc Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry
    Letitia D Smith
    Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Melbourne, Victoria 3010, Australia
    Breast Cancer Res 13:R14. 2011
    ..We sought to test the value of selecting women for BRCA1 mutation testing on the basis of family history and/or breast tumour morphology criteria as well as the value of testing for large genomic alterations in BRCA1...
  3. pmc The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer
    Esther M John
    Clinical and Genetic Epidemiology Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
    Breast Cancer Res 6:R375-89. 2004
    ....
  4. doi An update on apocrine lesions of the breast
    F P O'Malley
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Histopathology 52:3-10. 2008
    ..This review will briefly summarize the morphological characteristics and risk associations of the spectrum of apocrine proliferations, but will focus on the updated molecular studies of both in situ and invasive apocrine carcinomas...
  5. ncbi The spectrum of apocrine lesions of the breast
    F P O'Malley
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Adv Anat Pathol 11:1-9. 2004
    ..Malignant apocrine lesions, including both in situ and invasive carcinoma, are also discussed...
  6. doi HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab
    Frances P O'Malley
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5
    Arch Pathol Lab Med 132:61-5. 2008
    ..Trastuzumab has been shown to only be effective in those patients whose cancers are HER2 positive by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH)...
  7. ncbi Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast
    Frances P O'Malley
    Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Mod Pathol 19:172-9. 2006
    ..1-97.4%), than for determining its presence (90.4%: 95% CI, 79.9-96.7%). We conclude that the diagnosis of FEA and its distinction from CCLs without atypia is highly reproducible with the use of available diagnostic criteria...
  8. ncbi JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer
    Michael Reedijk
    Department of Surgical Oncology, University of Toronto, Toronto, ON, Canada, M5G 2M9
    Breast Cancer Res Treat 111:439-48. 2008
    ..As JAG1 is a target of several oncogenic signaling pathways, and is a ligand for Notch, these data provide novel insights into signaling that may contribute to progression of early stage breast cancer...
  9. pmc Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors
    Anita L Bane
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 117:183-91. 2009
    ..To elucidate novel genes involved in these two spectra of breast tumorigenesis we performed global gene expression analysis on breast tumors from germline BRCA1 and BRCA2 mutation carriers...
  10. ncbi Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast
    Teresa L Mastracci
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    Genes Chromosomes Cancer 45:1007-17. 2006
    ..This genomic signature, common to ALH and LCIS, suggests a role for the acquisition of novel genomic alterations in the aberrant cellular proliferation that defines lobular neoplasia...
  11. ncbi HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry
    Louise A Quenneville
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer 95:2068-75. 2002
    ..The Ontario Familial Breast Cancer Registry collects clinical and family history data in familial breast carcinoma cases, and unselected Ashkenazi breast carcinomas, and acts as a tumor tissue repository...
  12. ncbi Invasive lobular carcinoma: to grade or not to grade
    Anita L Bane
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Canada
    Mod Pathol 18:621-8. 2005
    ....
  13. doi Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort
    Anna Marie Mulligan
    Department of Laboratory Medicine, St Michael s Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 14:4168-74. 2008
    ..Subsequent to this validation, we examined outcome in specific subgroups defined using TMA data...
  14. ncbi Intranodal papillary epithelial proliferations: a local process with a spectrum of morphologies and frequent association with papillomas in the breast
    Fouad I Boulos
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon Departments of Psychiatry Pathology Pathology and Preventive Medicine, Vanderbilt University Medical Center, Nashville, TN Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, ON, Canada
    Am J Surg Pathol 38:383-8. 2014
    ....
  15. ncbi Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
    Rosemary E Mueller
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Genes Chromosomes Cancer 39:288-97. 2004
    ..Our results suggest that TOP2A gene amplification in breast tumors does not predict high expression of topoisomerase II alpha protein...
  16. doi Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer
    Catherine L Forse
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada
    Breast Cancer Res Treat 137:709-19. 2013
    ..001). PODXL has the potential to be a useful biomarker for identifying good prognosis patients in characteristically poor prognosis breast cancer groups and may impact treatment of women with this disease...
  17. doi EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry
    Anita L Bane
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Breast Cancer Res Treat 127:831-9. 2011
    ..EMSY amplification does occur independently of CCND1 amplification in a minority of familial breast cancers, supporting its role as a possible breast cancer oncogene...
  18. doi Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study
    Pamela J Goodwin
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario
    J Clin Oncol 30:19-26. 2012
    ..To compare breast cancer prognosis in BRCA1 and BRCA2 mutation carriers with that in patients with sporadic disease...
  19. ncbi Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer
    Reuben J Broom
    Princess Margaret Hospital, Toronto, Canada
    Anticancer Res 29:1557-62. 2009
    ..Changes in the receptor profile between primary and metastatic breast cancer tissue have been suggested. The degree of hormone receptor discordance in archival paired pathological samples was evaluated...
  20. pmc CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry
    Anna Marie Mulligan
    Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael s Hospital and the Department of Laboratory Medicine, St Michael s Hospital, Toronto, Ontario, Canada Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Cancer 117:1350-9. 2011
    ....
  21. pmc Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers
    Anita Bane
    Department of Pathology and Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, 711 Concession St, Hamilton, ON, Canada
    Breast Cancer Res Treat 140:195-205. 2013
    ..Whereas the presence of these markers is correlated with several poor prognostic features and the basal-like subtype of breast cancer, they do not predict OS. ..
  22. pmc Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry
    Anna Marie Mulligan
    Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael s Hospital, University of Toronto, Ontario, Canada
    Clin Cancer Res 19:336-46. 2013
    ..Chemokines could play a role in attracting these cells and contribute to tumor progression. We explored tumoral expression of CXCL10 and determined the relationship between CXCL10 and lymphocytic infiltrate in a cohort of breast cancers...
  23. doi Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre, The University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
    Breast Cancer Res Treat 131:541-51. 2012
    ..5. An appropriately powered meta-analysis is required to discriminate the predictive value of these three candidate markers...
  24. doi Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy
    Andrea Grin
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada
    Am J Surg Pathol 33:1615-23. 2009
    ..Patterns and extent of ER and CK5 staining, when used together, are valuable adjunct stains to differentiate usual duct hyperplasia from atypical proliferations within papillary lesions on core biopsy...
  25. ncbi FISH detection of HER2 amplification in breast cancer
    Rosemary E Mueller
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
    Methods Mol Biol 204:353-67. 2002
  26. doi Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study
    Kathleen I Pritchard
    Ontario Clinical Oncology Group, McMaster University, Hamilton, Canada
    J Clin Oncol 30:1274-9. 2012
    ..2-[(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) is potentially useful in assessing lymph nodes and detecting distant metastases in women with primary breast cancer...
  27. ncbi HER2 and responsiveness of breast cancer to adjuvant chemotherapy
    Kathleen I Pritchard
    Toronto Sunnybrook Regional Cancer Centre and the University of Toronto, Toronto, ON, Canada
    N Engl J Med 354:2103-11. 2006
    ....
  28. doi Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods
    Andrea Grin
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
    Arch Pathol Lab Med 133:31-7. 2009
    ..There is no standardized method for estimating the extent of DCIS, although serial sequential sampling with mammographic correlation is considered an accurate method...
  29. ncbi Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer
    Anna Marie Mulligan
    Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 106:39-47. 2007
    ..Furthermore, high expression of IR is independently and significantly associated with more favorable clinical outcomes. Follow-up intervention research is recommended...
  30. ncbi Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry
    Meghan J Walker
    Division of Prevention and Cancer Control, Cancer Care Ontario, 620 University Avenue, Toronto, ON, M5G 2L7, Canada
    Fam Cancer 13:163-72. 2014
    ..80, 95 % CI 1.18-51.50) compared with screen-detected cancers. Screening mammography may be effective for women with a first-degree family history of breast cancer, irrespective of level of familial risk...
  31. doi Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses
    Kiran Jakate
    Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada
    Am J Surg Pathol 36:544-51. 2012
    ....
  32. ncbi High-level JAG1 mRNA and protein predict poor outcome in breast cancer
    Brendan C Dickson
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Mod Pathol 20:685-93. 2007
    ....
  33. doi Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program
    Victoria A Kirsh
    Prevention and Cancer Control, Cancer Care Ontario, 620 University Ave, Toronto, ON M5G 2L7, Canada
    J Natl Cancer Inst 103:942-50. 2011
    ..Few studies have compared the prognostic value of tumor characteristics by type of breast cancer diagnosed in the interval between mammographic screenings with screen-detected breast cancers...
  34. ncbi E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast
    Teresa L Mastracci
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    Mod Pathol 18:741-51. 2005
    ..These cases lacking both protein expression and gene alterations suggest that another mechanism is involved, possibly as early as at the hyperplastic stage, causing silencing of the E-cadherin complex...
  35. ncbi Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status
    Yvan C Bedard
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto
    Acta Cytol 47:979-84. 2003
    ..Boxborough, Massachusetts, U.S.A.) is comparable to the findings of immunohistochemistry on corresponding surgically removed tissue...
  36. pmc A role for the TGFbeta-Par6 polarity pathway in breast cancer progression
    Alicia M Viloria-Petit
    Center for Systems Biology, Samuel Lunenfeld Research Institute, Room 1078 Mount Sinai Hospital, 600 University Avenue, Toronto, ON, Canada M5G 1X5
    Proc Natl Acad Sci U S A 106:14028-33. 2009
    ..These studies thus reveal a key role for polarity signaling and the control of morphologic transformation in breast cancer metastasis...
  37. pmc Improving work-up of the abnormal mammogram through organized assessment: results from the ontario breast screening program
    May Lynn Quan
    Foothills Medical Center, University of Calgary, Calgary, Alberta Cancer Care Ontario Dalla Lana School of Public Health, University of Toronto Sunnybrook Health Sciences Centre, University of Toronto and St Michaels Hospital, University of Toronto, Toronto, Ontario, Canada
    J Oncol Pract 8:107-12. 2012
    ....